What The Cure Trap Missed

Six days ago, I put The Cure Trap out as a free PDF. No publisher, no paywall, no waiting a year for a second edition. That was a choice about speed, but it also gives it one other advantage.

A traditionally published book is finished the day it goes to press. This one isn’t. Readers have been reading it, finding the gaps, and telling me about them, and I can fold what they find back into the book in days instead of years. That is the whole advantage of publishing this way. The book is a living document, and this post is its changelog in plain language: what was missed, what was wrong, who spotted it, and what the next edition will add.

Thanks to the reader who did most of the heavy lifting this week: John Mauremootoo, who read the whole book and sent in several concrete suggestions.

The invitation still stands. I asked for pushback, not praise. So far the response has been largely generous, which I appreciate, but if you think something in the book is wrong, or missing, or not said loudly enough, write to me at tmrwedition.com/ps.

I will keep adding to this post as more comes in, each addition dated. When enough accumulates, or a print run gets funded, it all folds into the second edition. Until then the book stays open.


1. The Biophysics Bridge: Parkinson’s as a SCAN disorder — John Mauremootoo

Chapter 13 has the biophysics framework and one paragraph on the SCAN, the somato-cognitive action network, but it doesn’t develop what the framework means for patients. That is what John asked for, and it is the most interesting science in this whole list.

A paper published in Nature in February (Ren and colleagues) identified the SCAN as the bridge between thought and action, and found that in Parkinson’s it becomes hyperconnected to the subcortex, stuck broadcasting a constant wall of noise that blocks intention from becoming movement. The striking result: aiming stimulation at the SCAN instead of the classical motor strip roughly doubled symptom relief, 56 percent responding against 22 percent, in a small trial of 36 patients.

It also reframes why the therapies we already have work. Levodopa, DBS and focused ultrasound don’t fix a spot. They act as filters for the noise. If Parkinson’s is a network disorder rather than a simple dopamine deficit, the goal changes from chasing dopamine to tuning the instrument. This has the potential to unlock a new era of personalized DBS targeting and non-invasive cortical targets.

Stated plainly, the caveat: that trial used stimulation through the scalp, not DBS, so the DBS part is the paper’s suggestion, not a demonstrated result. The bet is on the trajectory of the research, not on a result that already exists.

2. Whole-person resilience — John Mauremootoo

My own routine is in the book, in Chapter 16: eight to ten hours of sleep, seventy minutes of exercise damn near every day, a boxing and balance class, studying languages again to force my brain into novel environments. But it sits there as a description of what I do, not as an approach anyone else could follow.

John asked for it to be set out explicitly: the lifestyle factors that build overall resilience, alongside specific treatments for specific conditions. He is right that the book should say so plainly. The next edition will lift that routine into an explicit approach.

The framing I am working with comes from something I wrote in January: “We are but specks in time on a beach that stretches to infinity. While the tide eventually takes us all, there is a profound beauty in getting the chance to shape the shore before it does.” The routine is the shaping. The framing is why it matters.

3. Triggers, facilitators, aggravators — John Mauremootoo

The framework underpins the whole umbrella argument, but it appears in one line, on page 51. John asked for clear definitions with examples, and a note that the boundaries are functional rather than sharp.

He is right, and the pesticide example makes it click: the same exposure can spark the disease process, facilitate its spread, and aggravate it after diagnosis. The next edition will put the definitions in Chapter 12, with that example.

4. Bets I have no stake in — John Mauremootoo

All five bets in Chapter 22 involve me. The disclosure paragraph says so. John said the chapter would be stronger with bets I have no stake in, and he is right. Three now make it in: the SCAN research, in the first section, the World Parkinson Congress, in the next section, and the PRO-21 Diet in section six.

His other two candidates stay as mentions here rather than full sections. A Parkinson’s version of Dale Bredesen’s multipronged approach to Alzheimer’s, properly tested: the point is the testing, not the specific protocol. And scaling up basic treatment in less well-resourced parts of the world: already a theme in Chapter 20, not yet framed as a bet.

One other candidate I considered: Jonathan Sackner-Bernstein’s dopamine reduction therapy. The science is interesting and it would test the field’s founding assumption. But until there is clearer evidence of measurable, real-world patient outcomes, it doesn’t meet the threshold. I could be wrong and will continue digging into it.

5. More funding for the World Parkinson Congress, More Often

The World Parkinson Congress is where my advocacy launched. Portland, Oregon, September 2016. I went knowing next to nothing and no one. People living with the condition were treated as equals there, given real time in the program to present their own experiences and perspectives. Seeing everything that was the WPC changed me.

The Congress runs once every three years, and three years is a long time in a degenerative disease. At the 2019 Congress in Kyoto I ended my talk wondering how many in attendance would be well enough to make it to the next one, and closed with Gandalf: “All we have to decide is what to do with the time that is given us.”

So the bet is this: fund the World Parkinson Congress every two years and fund it better, not just more often: more discussion and less one-way lectures, more patient time at the centre of the program, and even more inclusive spaces.

Eli Pollard, who has run the Congress since it was founded in 2004 by Dr. Stanley Fahn, once told me about a researcher giving a talk on tremor, stopped by a patient in the audience: “I really liked your talk, but my tremor doesn’t really bother me. The reality is I can’t sleep. When are you going to do research on sleep?” The researcher was stumped. That exchange is the whole book in miniature, and it is what the Congress exists for.

6. Test the PRO-21 diet

I interviewed Laurie Mischley back in 2017, about nutrition and the brain. In July 2025 her team published a follow-up: ten years of data from 2,290 people with Parkinson’s, distilled into a diet of twenty-one food-related behaviours: heavy on fresh food, nuts and seeds, olive oil and fish, light on dairy, meat, canned food and sugar. The people who stuck to it most closely progressed 43 percent more slowly, and it outperformed the Mediterranean and MIND diets.

The bet is not the diet, per se. It is the trial. The data is observational, an association not proof, and the diet is demanding enough that cost and feasibility are real barriers. Mischley’s own paper says what is needed next is an intervention trial, and nobody will fund one, because nobody owns a diet. So the bet is this: fund the trial, and measure it with her own ruler- the PRO-PD scale, thirty-three sliders patients fill themselves, which catches changes the UPDRS misses.


Corrections

This post is also where corrections go, not just additions. Two, so far.

In Chapter 20 I wrote that Deborah Brooks’ pushback came the moment I finished asking the council to fund multidisciplinary care-and-trial centers. It actually happened about eighteen minutes later and several other questions passed first. The gist of what she said is backed up, a colleague in the room wrote it down within the hour, and the session’s own recording shows her pushing back on cost later in the discussion. But the timing as I wrote it compresses the reality of the scene.

Also in Chapter 20, after praising Jonathan Silverstein’s foundation, I wrote that if we’d had a patient like him, “willing to get his hands dirty,” at the helm of the Michael J. Fox Foundation, we’d be much further along today than we are. The sentence sets Jonathan against Michael, and the contrast lands on Michael as the figurehead who won’t do the work. That is not fair to him, he is a patient too and his work built the foundation at the centre of so much of the PD world. The next edition drops the comparison.


That’s the first instalment. I will keep adding to this post as more comes in, each addition dated. When enough accumulates, or a print run gets funded, it all folds into the second edition.

Until then the book stays open, and the invitation stands: tell me where I got it wrong. Write to me at tmrwedition.com/ps.

Leave a Reply